Re: BLQ Data

On 3/10/2015, at 5:45 AM, Ahmed Suleiman <[email protected]<mailto:[email protected]>> wrote: Hi Brady, Have a look at this recently published paper by Ron Keizer and colleagues; will answer your question. "Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses". Keizer et al, Pharmacol Res Perspect, 2015. Best Regards, On Fri, Oct 2, 2015 at 4:22 PM, Moffett, Brady S. <[email protected]<mailto:[email protected]>> wrote: I am working with TDM data and am wondering when to use the M3 method for dealing with BLQ data, or, when to just exclude data? For instance: If I have <1% BLQ data in a large dataset (~1000 patients), should I just exclude those patients/values? If I just have one patient with one value BLQ, is it worth using the M3 method for that one patient? Is there a breakpoint for which using these methods does/does not make a difference? Thanks in advance... ______________________________________________________________________ CONFIDENTIALITY NOTICE: The information in this e-mail may be confidential and/or privileged. If you are not the intended recipient or an authorized representative of the intended recipient, you are hereby notified that any review, dissemination, or copying of this e-mail and its attachments, if any, or the information contained herein is prohibited. If you have received this e-mail in error, please immediately notify the sender by return e-mail and delete this e-mail from your computer system. Thank you. ______________________________________________________________________ -- Ahmed Abbas Suleiman, MSc PhD Candidate at Bonn University Institute of Pharmacology - Clinical Pharmacology Unit Hospital of the University of Cologne Gleueler Str. 24, 50931 Cologne, Germany